Veeva Systems (NYSE: VEEV) is helping pharmaceutical companies create and sell new drugs more efficiently. It's cloud-based software platforms Veeva CRM and Veeva Vault have become industry-standards; deeply embedded with Big Pharma's largest companies.

There's an upcoming catalyst next year, as Veeva's CRM platform will migrate from being hosted by Salesforce to its own infrastructure. That will unlock opportunities for it to develop new software products -- perhaps even beyond life sciences -- to make the pie larger with its largest customers.

As interest rates fall, it's likely new VC funding will flow into smaller biotech companies and will unlock a new SMB revenue stream as well.

7investing CEO Simon Erickson describes both of these catalysts, as well as why he believes the stock is undervalued, in today's 7investing podcast.

To see all of our official stock recommendations and our monthly Best Buys, get started with 7investing at ⁠7investing.com/subscribe⁠. Your first week of our premium membership is entirely free!

Get the future of podcasts.